Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma.
about
Tenascin-C: Form versus functionImmunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteMechanisms of action of therapeutic antibodies for cancerPrognostic value of the preoperative immunological profile in patients with glioblastoma.Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models.Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.A highly functional synthetic phage display library containing over 40 billion human antibody clones.Advances in tenascin-C biology.Tenascin-C: Exploitation and collateral damage in cancer managementTrial Watch: Immunostimulatory cytokines.Emphasising the European Union's Commitment to Cancer Research: a helicopter view of the Seventh Framework Programme for Research and Technological Development.Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.Immunocytokines: a review of molecules in clinical development for cancer therapy.Molecular characteristics and potential therapeutic targets in Merkel cell carcinoma.The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity.Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia.Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation.The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate.Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.Systemic Therapy for Merkel Cell Carcinoma: What's on the Horizon?The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.Antibody-cytokine fusion proteins for cancer immunotherapy: an update on recent developments.Function of neuronal nitric oxide synthase enzyme in temozolomide-induced damage of astrocytic tumor cells.Emerging classes of armed antibody therapeutics against cancerDifferential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug deliveryImmunocytokinesThe antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model
P2860
Q27023815-7E266DA4-941A-4C86-98A9-92BBCB87A6FBQ28066935-D8745DED-FC18-4FA6-8D3E-8C7C156C7B9FQ28385366-A29EDB19-BED8-4015-8D6B-E429FEDAC28BQ33887213-BE69B08F-F09E-49FB-AD97-6716431CE0E4Q34687012-F76790AC-5EAE-4DC1-BC75-8E4F94433CAEQ35163167-6642F667-FD91-4218-8C67-2C24648F5E2DQ35192223-B7FAAA8B-51D2-4121-A032-155FAC7B9478Q35214557-FEC945AF-0171-40E3-B14F-E18E7D344594Q35577959-D3A94813-A1C4-4EDC-8736-136840DF380BQ36057492-12826EA1-599F-47C7-A46C-DAC7458D080AQ36349630-91525F95-D772-4AE0-A1F4-92810317F4C9Q37970682-16FC69CA-E11F-4F15-9D74-B209E1D49CC3Q38132742-01843FDF-22E1-4019-83D3-AC16F9A58E7CQ38714104-374CBDC2-0376-4D4D-9329-098F2A3B15C5Q38905573-2EC4C8BB-3A0F-4F70-A32E-1192AA2AF7E1Q38988662-2609DD86-D566-457D-9331-CBD19F54F7A5Q39100229-8549E5B8-70D8-49EF-B531-D5D6B5FEF6C8Q39205186-30364F78-7AEF-4785-A42D-9F68389400EFQ39448373-11F24E14-8882-4AEF-965C-6D48AACF6C39Q39609067-0FE20A56-0984-4B05-BCFA-0B31AB076FABQ41458291-27D6D971-F7E8-46E8-8583-64075E71035CQ50864449-441EF36D-344C-41E1-B267-73AF888EB63BQ51786117-E8A2B57C-00F7-4EF9-9B1C-609C277BE90EQ52649753-9827E2CE-A0E2-40E3-964B-1A01798AC94DQ57911948-D61D958A-6DCD-477F-9CE9-7AB2ED2BA140Q57911973-473D4FB6-0DA4-41CB-A108-49EC70B608F9Q57911975-951A5A0F-599F-4718-B300-CD67DE0DB976Q57912004-37B5563F-0660-486C-99F5-962A76AE8C26
P2860
Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Combination of temozolomide wi ...... the treatment of glioblastoma.
@ast
Combination of temozolomide wi ...... the treatment of glioblastoma.
@en
Combination of temozolomide wi ...... the treatment of glioblastoma.
@nl
type
label
Combination of temozolomide wi ...... the treatment of glioblastoma.
@ast
Combination of temozolomide wi ...... the treatment of glioblastoma.
@en
Combination of temozolomide wi ...... the treatment of glioblastoma.
@nl
prefLabel
Combination of temozolomide wi ...... the treatment of glioblastoma.
@ast
Combination of temozolomide wi ...... the treatment of glioblastoma.
@en
Combination of temozolomide wi ...... the treatment of glioblastoma.
@nl
P2093
P2860
P356
P1476
Combination of temozolomide wi ...... the treatment of glioblastoma.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605832
P407
P577
2010-08-24T00:00:00Z
P5875
P6179
1029492385